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Population Science
Effects of Prehypertension and Hypertension Subtype on
Cardiovascular Disease in the Asia-Pacific Region
Hisatomi Arima, Yoshitaka Murakami, Tai Hing Lam, Hyeon Chang Kim, Hirotsugu Ueshima,
Jean Woo, Il Suh, Xianghua Fang, Mark Woodward, on behalf of the Asia Pacific Cohort
Studies Collaboration
Abstract—The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of
High Blood Pressure defined blood pressure (BP) levels of 120 to 139/80 to 89 mm Hg as prehypertension and those
of 140/90 mm Hg as hypertension. Hypertension can be divided into 3 categories, isolated diastolic (IDH; systolic BP
140 mm Hg and diastolic BP90 mmHg), isolated systolic (systolic BP140 mm Hg and diastolic BP90 mmHg),
and systolic-diastolic hypertension (systolic BP 140 mm Hg and diastolic BP 90 mmHg). Although there is clear
evidence that isolated systolic hypertension and systolic-diastolic hypertension increase the risks of future vascular
events, there remains uncertainty about the effects of IDH. The objective was to determine the effects of prehypertension
and hypertension subtypes (IDH, isolated systolic hypertension, and systolic-diastolic hypertension) on the risks of
cardiovascular disease (CVD) in the Asia-Pacific Region. The Asia Pacific Cohort Studies Collaboration is an individual
participant data overview of cohort studies in the region. This analysis included a total of 346570 participants from 36
cohort studies. Outcomes were fatal and nonfatal CVD. The relationship between BP categories and CVD was explored
using a Cox proportional hazards model adjusted for age, cholesterol, and smoking and stratified by sex and study.
Compared with normal BP (120/80 mmHg), hazard ratios (95% CIs) for CVD were 1.41 (1.31–1.53) for
prehypertension, 1.81 (1.61–2.04) for IDH, 2.18 (2.00–2.37) for isolated systolic hypertension, and 3.42 (3.17–3.70) for
systolic-diastolic hypertension. Separately significant effects of prehypertension and hypertension subtypes were also
observed for coronary heart disease, ischemic stroke, and hemorrhagic stroke. In the Asia-Pacific region, prehyperten-
sion and all hypertension subtypes, including IDH, thus clearly predicted increased risks of CVD. (Hypertension. 2012;
59:1118-1123.) ● Online Data Supplement
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Cardiovascular disease (CVD) is a leading cause ofpremature death and disability globally.1,2 Elevation of
blood pressure (BP) is one of the most important preventable
causes of CVD: 54% of stroke and 47% of coronary heart
disease worldwide have been attributed to it.3 The relation-
ship of BP with the risk of CVD is continuous down to
systolic (SBP) and diastolic BP (DBP) levels of 110 to 115
and 70 to 75 mmHg, respectively.4,5 There is also continuous
association between pulse pressure and CVD.6 However,
current guidelines for management of hypertension7–9 recom-
mend classification of BP levels based on cutoff values to
simplify diagnostic and treatment approaches in clinical
practice.
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure defined BP levels of 120 to 139/80 to 89
mm Hg as prehypertension based on the evidence of a
modest increase in cardiovascular risk among individuals
with such levels.7 Because of its high prevalence,10,11 a
substantial part of the burden of CVD occurs among
people with prehypertension.12–14
Hypertension is usually defined as BP levels of 140/90
mmHg7–9 and can be divided into 3 categories, isolated
diastolic hypertension (IDH), isolated systolic hypertension
(ISH), and diastolic with systolic hypertension (systolic-
diastolic hypertension [SDH]).15 A number of observational
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studies have demonstrated clear associations of ISH and SDH
with future cardiovascular events.16–21 In contrast, there has
been uncertainty surrounding the effects of IDH on the risks
of CVD.16–23 As a result, patients with IDH, which consti-
tutes 14% to 24% of the total hypertensive population,18,20,24
are less likely to receive clinical attention and BP-lowering
treatment than those with ISH or SDH.18–20
The Asia Pacific Cohort Studies Collaboration (APCSC) is
an individual participant data overview of cohort studies in
the region.25,26 Previous studies from the APCSC have focused
on the continuous effects of BP on the risk of CVD.5,6 In the
present analysis, we provide detailed information about the
associations between prehypertension and hypertension sub-
types (IDH, ISH, and SDH) and the risk of CVD.
Methods
All of the APCSC cohort studies recorded date of birth (or age), sex,
and BP at baseline and date of death (or age at death) during
follow-up. Studies were excluded if enrollment depended on having
a particular condition of a risk factor. For this report, only partici-
pants aged from 30 to 90 years at baseline with information on
smoking status and total cholesterol were included. Studies were
classified as Asian if participants were recruited from mainland
China, Hong Kong, Japan, Korea, Singapore, Taiwan, and Thailand,
and as ANZ (predominantly White) if participants were recruited
from Australia or New Zealand. In most studies, BP was measured
at rest in the seated position using a standard mercury sphygmoma-
nometer.5,6 Smoking status was self-reported as never smoker,
ex-smoker, or current smoker. Because the APCSC is based on
existing data, no ethics approval was needed for the present study.
All of the studies reported deaths attributed to CVD; some studies
also reported nonfatal CVD events, defined as events that did not
result in death within 28 days. All of the analyses use pooled fatal
and nonfatal outcomes, taking the first recorded event as the index
event. Outcomes were classified according to the Ninth Revision of
International Classification of Disease. The outcomes considered in
this analysis were coronary heart disease (Ninth Revision of Inter-
national Classification of Disease 410–414), hemorrhagic stroke
(431.0–432.9), ischemic stroke (433.0–434.9), and total CVD (390–
459). Because most studies identified events using record linkage,
verification of stroke was not routinely reported. All of the data provided
were checked for completeness and consistency and recoded, when
necessary, to ensure maximize comparability across cohorts. Summary
reports were referred back to the principal investigators of each
collaborating study for review and confirmation.
Cox proportional hazard models were used to examine the effects
of BP category on CVD. Baseline hazards were allowed to differ by
sex and cohort by using these variables as strata in the Cox models.
Age, total serum cholesterol, and smoking status were included as
confounders in all of the models. BP categories were classified as
normal BP (SBP 120 mm Hg and DBP 80 mmHg), prehyper-
tension (SBP 120–139 mm Hg and/or DBP 80–89 mmHg), IDH
(SBP140 mm Hg and DBP90 mmHg), ISH (SBP140 mm Hg
and DBP90 mmHg), and SDH (SBP140 mm Hg and DBP90
mmHg). Normal BP was taken as the reference category for hazard
ratios (HRs). Subgroup analyses by sex, age (65 years and 65
years), and region (Asia/ANZ) were performed for total CVD.
Comparison of the effects of BP categories between subgroups was
done by adding interaction terms to the statistical models. All of the
statistical analyses were performed using SAS release 9.20 (SAS
Institute Inc, Cary, NC).
Results
Baseline and Follow-Up Data
Data from 36 cohort studies, which included 346570 partic-
ipants, were included in the present analyses (Table S1,
available in the online-only Data Supplement). The mean age
of participants at baseline was 48 years, 41% were women,
and 78% were from Asia. Percentage of BP categories was
38%, 38%, 6%, 8%, and 11% for normal BP, prehyperten-
sion, IDH, ISH, and SDH, respectively. During a mean
follow-up of 7 years, 8598 people (2.5%) experienced a CVD
event, 3270 (0.9%) experienced coronary heart disease, 1503
(0.4%) experienced ischemic stroke, and 1015 (0.3%) expe-
rienced hemorrhagic stroke.
Effects of BP Category on the Risk of CVD
Compared with normal BP, prehypertension and all of the
hypertension subtypes were clearly associated with increased
risks of CVD even after controlling for age, sex, cholesterol,
and smoking (Figure 1). The risks of CVD increase in the
order of prehypertension, IDH, ISH, and SDH (P0.0001 for
normal BP versus prehypertension;0.0001 for prehyperten-
sion versus IDH; 0.0013 for IDH versus ISH; and 0.0001
for ISH versus SDH). When prehypertension was divided into
isolated diastolic prehypertension (SBP 120 mm Hg and
DBP 80 – 89 mm Hg), isolated systolic prehypertension
(SBP 120–139 mm Hg and DBP 80 mmHg), and systolic-
diastolic prehypertension (SBP 120–139 mm Hg and DBP
80–89 mmHg), HRs were 1.08 (95% CI, 0.91–1.29), 1.42
(1.30–1.56), and 1.47 (1.34–1.61), respectively. Effects of
prehypertension and hypertension subtypes were comparable
between fatal CVD (HR, 1.33 [95% CI, 1.20–1.46] for
prehypertension, 1.77 [1.51–2.06] for IDH, 2.07 [1.87–2.29]
for ISH, and 3.16 [2.87–3.49] for SDH) and nonfatal CVD
(1.57 [1.39–1.76] for prehypertension, 2.04 [1.72–2.42] for
IDH, 2.38 [2.09–2.72] for ISH, and 3.93 [3.48–4.43] for
SDH). Separately, significant effects of prehypertension and
hypertension subtypes were also observed for coronary heart
disease, ischemic stroke, and hemorrhagic stroke (Figure 1),
and the risks of each outcome increased in the order of
prehypertension, IDH, ISH, and SDH (normal BP versus
prehypertension, P0.0001 for all; prehypertension versus
IDH, P0.0001 for all; IDH versus ISH, P0.95, 0.0008,
and 0.09 for coronary heart disease, ischemic stroke, and
hemorrhagic stroke, respectively; and ISH versus SDH,
P0.0001 for all). The relationship of each BP category with
coronary heart disease was weaker than for ischemic or
hemorrhagic stroke. Between 2 stroke subtypes, the associa-
tion with hemorrhagic stroke was stronger than for ischemic
stroke.
Among subjects of the present analysis, a total of 121051
participants had information on BP-lowering treatment. Com-
pared with normal BP without treatment, number of events
per subject and multivariable-adjusted HR (95% CI) for
development of CVD were 1041/39479 and 1.25 (95% CI,
1.10–1.42) for prehypertension without treatment, 106/3028
and 1.53 (95% CI, 1.19–1.95) for IDH without treatment,
1365/19644 and 1.62 (95% CI, 1.43–1.85) for ISH without
treatment, 1042/12887 and 2.41 (95% CI, 2.10–2.75) for
SDH without treatment, and 1407/18231 and 2.77 (95% CI,
2.43–3.16) for treated hypertension.
Effects of BP Category on the Risk of Total CVD
by Subgroups
There were similar effects of prehypertension and hyperten-
sion subtypes on the risks of CVD between male and female
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participants (P for homogeneity0.16; Figure 2). On the
other hand, effects of each BP category on the risks of CVD
were larger among subjects aged 65 years compared with
those aged 65 years (P for homogeneity 0.001), and there
were no clear effects of prehypertension on CVD among
older subjects. Likewise, there were stronger associations
between each BP category and the risk of CVD among
participants recruited from Asia than from ANZ (P for
homogeneity 0.001). A higher HR for each BP category,
among Asian subjects compared with ANZ subjects, was also
observed for coronary heart disease (P for homogene-
ity0.02), ischemic stroke (P for homogeneity0.02), and
hemorrhagic stroke (P for homogeneity0.002; Figure S1,
available in the online-only Data Supplement). Although the
number of events is limited, particularly in ANZ, similar
patterns were observed between BP categories and each
subtype of CVD among participants from Asia and ANZ.
Heterogeneity in the effects of each BP category across
subgroups defined by age was also observed for coronary
heart disease (P for homogeneity0.04), ischemic stroke
(P for homogeneity 0.001), and hemorrhagic stroke (P for
homogeneity0.002).
Discussion
Findings from the current study, based on prospective data from
350 000 individuals from the Asia-Pacific region, provide
good evidence of clear associations of prehypertension and all
types of hypertension, including IDH, with future risks of CVD.
Separately, significant associations were observed for coronary
heart disease, ischemic stroke, and hemorrhagic stroke. These
associations remained significant after controlling for the con-
founding effects of age, sex, cholesterol, and smoking. Further-
more, increased risks of CVD associated with prehypertension
and hypertension subtypes were observed across subgroups
defined by age, sex, and geographical region, although there was
a certain degree of heterogeneity in the strength of the associa-
tions by age and region.
Large-scale observational studies have demonstrated that
prehypertension is associated with increased risks of premature
death and cardiovascular morbidity, particularly at BP levels
of 130 to 139/85 to 89 mmHg.13,27–33 Likewise, a number of
large-scale cohort studies have reported significant effects of
prehypertension separately on the risks of stroke13,29,30,32 and
coronary heart disease.13,29 The present analysis from the
APCSC confirmed the results from the previous observational
studies and provided more detailed information about the sepa-
rately significant associations of prehypertension with all of the
major types of CVD, including ischemic and hemorrhagic stroke
in the Asia-Pacific region.
Despite the clear evidence of ISH and SDH as important
predictors of future vascular events,16–21 a number of obser-
vational studies have failed to show significant effects of IDH
on the risks of cardiovascular morbidity or mortality, probably
because of the smaller number of subjects with IDH.16–19,22
However, 2 recent large-scale cohort studies conducted in China
have demonstrated clear effects of IDH on the risks of coronary
heart disease, stroke, and total CVD.20,21 The analysis reported
Coronary heart disease
Hazard ratio 
(95% CI) Events
Prehypertension
Isolated diastolic hypertension
Isolated systolic hypertension
Systolic-diastolic hypertension
1.31 (1.14 to 1.50)
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Cardiovascular disease
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Figure 1. Effects of prehypertension and hypertension subtype on the risk of cardiovascular disease and its major subtypes. Hazard
ratios were adjusted for age, total cholesterol, and smoking and stratified by sex and study. Normal blood pressure was used as the
reference group. The center of each solid box is plotted against the point estimate, and the horizontal lines are drawn to the 95% con-
fidence limits. Areas of the boxes are proportional to the reciprocal of the variance of the estimates.
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here supports the findings obtained from the 2 studies conducted
in China and demonstrates that the effects of IDH on the risks of
CVD are generalizable to Western populations, as well as Asian
populations.
In the present analysis, the highest risk of CVD was
observed among patients with elevated SBP and DBP (SDH).
The second highest risk was among patients with ISH, and the
third highest was among those with IDH. Similar association
was observed for each of the major CVD subtypes. There was
also consistency in the ranking between hypertension sub-
types across subgroups defined by age, sex, and geographical
region. The same ranking in the effects of hypertension
subtypes was also reported from other cohort studies.19–21
The Stroke Prevention Project in China has investigated the
effects of hypertension subtype on stroke among 26587
Chinese subjects and found that HRs were 2.16 for IDH, 2.35
for ISH, and 2.96 for SDH compared with normotensives.20
Likewise, the China Hypertension Epidemiology Follow-Up
Study has demonstrated that HRs of CVD incidence were
1.59 for IDH, 1.78 for ISH, and 2.73 for SDH among 169871
participants from China.21 A prospective cohort study of 3267
men in Finland has also shown that HRs of stroke incidence
were 1.14 for IDH, 1.36 for ISH, and 2.71 for SDH.19 One
possible reason for lower risks of CVD in IDH may involve
younger age of patients with IDH than those with ISH or
SDH.16–22 These findings support the hypothesis that the risks
of CVD increase in the order of IDH, ISH, and SDH.
Another key result from the present analysis was the
heterogeneity in the effects of prehypertension and hyperten-
sion subtypes on different types of CVD and heterogeneity in
the effects of each BP category across subgroups defined by
age or geographical region. These findings are directly in line
with the results of large-scale observational studies that had
identified smaller effects of BP on the risks of coronary heart
disease than on the risks of stroke, stronger effects of BP on
intracerebral hemorrhage than on the risks of ischemic stroke,
and stronger effects of BP on CVD among younger or Asian
subjects compared with older or Western subjects.4,5,34 Al-
though there were no clear effects of prehypertension on
CVD among subjects aged 65 years in the present analysis,
similar findings were also reported from other cohort stud-
ies.14,33 The regional difference observed in the present
analysis might be explained, at least in part, by the fact that
Asian subjects were younger than Western subjects (mean, 46
versus 53 years) despite our adjustment for age, and stroke,
which was more strongly associated with BP than coronary
heart disease, was more common in Asian studies than in
ANZ studies. Heterogeneity in the effects of each BP cate-
gory in the present analyses are also consistent with the
results of randomized, controlled trials, which demonstrated
heterogeneity in the magnitude of the effects of BP-lowering
treatment on different types of CVD or across subgroups
defined by age or region.35–40
The strengths of APCSC include the large amount of data
and the strong collaboration, involving several ethnic groups.
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Figure 2. Effects of prehypertension and hypertension subtype on the risk of total cardiovascular disease by sex, age, and geographi-
cal region. Conventions are as for Figure 1.
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As far as we are aware, this is the largest study to report the
effects of prehypertension and hypertension subtypes on
the risks of CVD. The number of individuals involved in the
present analysis of APCSC means that the overall estimates
are more precise than those in most previous studies. The
main weaknesses of APCSC relate to nonstandardization of
data collection methods. All of the cohorts were begun before
the collaboration was initiated, without a common protocol.
This might have introduced variations in measurement
error in determining BP levels and possible misclassifica-
tion of events, particularly with respect to stroke subtype.
Reliable verification of stroke subtype requires imaging or
autopsy data, and although it is likely that such informa-
tion formed the basis of most reporting, this could not
always be confirmed.
Perspectives
In the Asia-Pacific region, prehypertension and all of the
hypertension subtypes were significantly associated with in-
creased risks of CVD. Because a large portion of the population
is classified as prehypertension or hypertension, population
strategy to lower BP at the community level, such as salt
reduction in commercial products, civil engineering to facilitate
walking, and a systematic large-scale educational effort, are
essential for reduction in the global burden of CVD. Further-
more, BP-lowering treatment should be initiated, and target BP
levels recommended by current guidelines7–9 adopted, among all
patients who require drug treatment, irrespective of hypertension
subtype (IDH, ISH, and SDH).41
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Table S1. Characteristics of study population 
  Baseline  Female Age (years)  
SBP 
(mmHg)  
DBP 
(mmHg)  
Cholesterol 
(mmol/l) Current 
Mean 
follow Number of events 
 Study Country years n (%) Mean SD  Mean SD  Mean SD  Mean SD smoker (%) up years CHD IS HS CVD 
Anzhen02 China 1992-93 4140 51 47 8  122 18  78 11  4.7 0.9 21 3 1 14 1 17 
Beijing Aging China 1992 1682 50 69 8  141 25  82 12  4.4 1.0 31 4 0 0 0 149 
Capital Iron & Steel Company China 1974-80 4423 0 46 7  124 19  81 12  4.9 1.0 74 13 74 86 61 220 
Fangshan China 1991-92 834 67 47 9  132 25  79 13  4.6 1.0 39 3 2 5 2 12 
Guangzhou Occupational China 1985-97 15641 36 44 7  114 16  76 10  5.3 1.2 43 8 20 0 18 60 
Huashan China 1990-92 1805 52 53 12  126 21  76 11  4.6 0.9 25 3 3 10 6 23 
Seven Cities Cohorts China 1987 6372 57 58 10  134 25  83 13  5.0 1.5 34 6 66 100 124 453 
Shanghai Factory Workers China  1972 9017 31 48 7  125 22  79 12  4.2 0.9 44 14 81 0 0 373 
Six Cohorts China 1982-86 14503 48 45 7  118 17  76 10  4.2 0.9 42 8 30 56 65 270 
Xi'an China  2964 1695 34 44 6  126 21  83 12  4.6 0.9 40 18 35 15 24 80 
Yunnan China 1992 2626 4 54 9  122 21  80 13  4.3 0.8 69 4 5 4 23 55 
Hong Kong Hong Kong 1985-91 175 52 78 5  149 22  80 12  5.3 0.9 18 2 4 0 0 12 
Aito Town Japan 1980-83 1094 59 51 9  137 23  80 13  4.7 0.9 28 15 10 0 4 39 
Akabane Japan 1985-86 1832 56 54 8  125 19  74 12  5.0 0.9 28 11 28 16 5 79 
Civil Service Workers Japan 1990-92 9225 33 47 5  126 18  75 11  5.2 0.9 38 7 1 0 1 12 
Hisayama Japan 1961 1545 56 56 11  135 26  78 13  4.1 1.0 43 19 88 224 66 438 
Konan Japan 1987-95 1106 56 54 14  131 19  79 11  4.9 0.9 30 6 2 7 3 24 
Miyama Japan 1988-90 413 62 59 9  129 23  77 12  5.1 0.9 24 7 0 0 0 1 
Ohasama Japan 1992-93 1905 65 58 11  127 17  72 12  5.0 0.9 21 4 4 27 10 52 
Saitama Japan 1986-90 3554 63 55 11  135 20  80 12  5.0 1.0 28 10 24 27 15 119 
Shibata Japan 1977 2328 58 57 11  131 21  78 12  4.6 1.2 33 16 67 75 36 340 
Shigaraki Town Japan 1991-97 3715 59 57 14  132 20  78 12  5.0 0.9 29 4 3 4 2 28 
Shirakawa Japan 1974-79 4389 54 50 11  127 22  77 13  4.7 0.9 35 17 65 39 31 192 
Tanno/Soubetsu Japan 1977 1970 53 51 7  133 20  82 10  4.9 1.0 39 15 24 10 16 73 
Singapore Heart Singapore 1982-97 1707 50 46 11  127 23  78 12  6.1 1.2 22 11 61 21 7 128 
Singapore NHS92 Singapore 1992 2469 53 44 10  121 20  71 12  5.5 1.0 18 6 33 13 4 76 
KMIC South Korea 1992 160236 33 44 7  122 14  80 10  5.0 0.9 38 4 278 432 325 1416 
CVDFACTS Taiwan 1988-96 4729 55 51 13  120 19  76 11  5.0 1.2 22 6 12 7 7 58 
EGAT Thailand 1985 3488 23 43 5  121 16  75 11  5.8 1.1 43 10 33 0 0 51 
TOTAL ASIA   268618 37 46 9  123 17  79 11  4.9 1.0 38 6 1054 1192 856 4850 
                      
Australian Longitudinal Study of 
Aging Australia 1992-93 1107 48 77 6 
 149 22  79 11  5.8 1.2 8 5 58 3 8 136 
Australian National Heart Foundation Australia 1989-90 7469 51 48 11  128 19  80 11  5.7 1.1 23 8 76 1 0 111 
Busselton Australia 1966-81 5561 51 52 14  143 26  80 13  6.1 1.3 33 24 1178 223 89 2011 
Melbourne Australia 1990-94 41139 59 55 9  138 20  77 12  5.5 1.1 11 9 323 11 35 550 
Newcastle Australia 1983-94 5729 50 52 10  133 20  80 11  5.9 1.1 23 9 134 3 8 198 
Perth Australia 1978-94 8470 47 48 11  132 20  82 11  5.9 1.2 24 13 186 4 10 294 
Fletcher Challenge New Zealand 1992-94 8477 28 48 13 
 127 17  78 11  5.5 1.1 22 6 261 66 9 448 
TOTAL ANZ   77952 52 53 11  135 21  78 12  5.6 1.1 17 10 2216 311 159 3748 
                      
TOTAL     346570 41 48 10  126 19  79 11  5.1 1.1 34 7 3270 1503 1015 8598 
SD indicates standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; ANZ, Australia and New Zealand. 
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Events
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939
841
544
155
273
533
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7
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49
8
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355
128
203
823
1 2 4
Hazard ratio
0.5 8 16
 
Figure S1. Effects of prehypertension and hypertension subtype on the risk of 
coronary heart disease, ischemic stroke and hemorrhagic stroke by 
geographical region 
Hazard ratios were adjusted for age, total cholesterol and smoking and stratified by 
sex and study. Normal blood pressure was used as the reference group. The center 
of each solid box is plotted against the point estimate and the horizontal lines are 
drawn to the 95% confidence limits. Areas of the boxes are proportional to the 
reciprocal of the variance of the estimates. 95% CI indicates 95% confidence interval. 
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Appendix S1: Asia Pacific Cohort Studies Collaboration membership 
 
APCSC Executive Committee 
M. Woodward (Chair), X. Fang, D.F. Gu, R. Huxley, Y. Imai, H.C. Kim, T.H. Lam, 
W.H. Pan, A. Rodgers, I. Suh, H. Ueshima 
 
Participating Studies and Principal Collaborators in APCSC 
Aito Town: A. Okayama, H. Ueshima, H. Maegawa; Akabane: M. Nakamura, N. Aoki; 
Anzhen02: Z.S. Wu; Anzhen: C.H. Yao, Z.S. Wu; Australian Longitudinal Study of 
Aging: Mary Luszcz; Australian National Heart Foundation: T.A. Welborn; Beijing 
Aging: Z. Tang; Beijing Steelworkers: L.S. Liu, J.X. Xie; Blood Donors’ Health: R. 
Norton, S. Ameratunga, S. MacMahon, G. Whitlock; Busselton: M.W. Knuiman; 
Canberra-Queanbeyan: H. Christensen; Capital Iron and Steel Company: X.G. Wu; 
CISCH: J. Zhou, X.H. Yu; Civil Service Workers: A. Tamakoshi; CVDFACTS: W.H. 
Pan; East Beijing: Z.L. Wu, L.Q. Chen, G.L. Shan; Electricity Generating Authority of 
Thailand: P. Sritara; Fangshan: D.F. Gu, X.F. Duan; Fletcher Challenge: S. 
MacMahon, R. Norton, G. Whitlock, R. Jackson; Guangzhou: Y.H. Li; Guangzhou 
Occupational: T.H. Lam, C.Q. Jiang; Hisayama: Y. Kiyohara, Y. Doi, T. Ninomiya; 
Hong Kong: J. Woo, S.C. Ho; Huashan: Z. Hong, M.S. Huang, B. Zhou; Kinmen: J.L. 
Fuh; Konan: H. Ueshima, Y. Kita, S.R. Choudhury; KMIC: I. Suh, S.H. Jee, I.S. Kim; 
Melbourne: G.G. Giles; Miyama: T. Hashimoto, K. Sakata; Newcastle: A. Dobson; 
Ohasama: Y. Imai, T. Ohkubo, A. Hozawa; Perth: the late K. Jamrozik, M. Hobbs, R. 
Broadhurst; Saitama: K. Nakachi; Seven Cities: X.H. Fang, S.C. Li, Q.D. Yang; 
Shanghai Factory Workers: Z.M. Chen; Shibata: H. Tanaka; Shigaraki Town: Y. Kita, 
A. Nozaki, H. Ueshima; Shirakawa: H. Horibe, Y. Matsutani, M. Kagaya; Singapore 
Heart: K. Hughes, J. Lee; Singapore NHS92: D. Heng, S.K. Chew; Six Cohorts: B.F. 
Zhou, H.Y. Zhang; Tanno/Soubetsu: K. Shimamoto, S. Saitoh; Tianjin: Z.Z. Li, H.Y. 
Zhang; Western Australia AAA Screenees: P. Norman, the late K. Jamrozik; Xi’an: Y. 
He, T.H. Lam; Yunnan: S.X. Yao. 
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